Welcome to InOncology.com

Discover how Boehringer Ingelheim is taking cancer on in order to transform patients' lives. Our long-term commitment to oncology is to pursue leading science to develop innovative cancer treatments across different tumor types.

LATEST CONGRESSES: OUR ACTIVITIES

Past event
ASCO GI 2021
ESMO 2021

Explore data presented at the ESMO 2021 virtual congress (Sep 16–21);

10 poster presentations

Past event
ESMO Asia 2020 congress
IASLC WCLC 2021

Explore data presented at the IASLC WCLC 2021 virtual meeting (Sep 8-14);

2 poster presentations

Past event
asco-2021
ASCO 2021

Discover our activities at the virtual ASCO annual meeting 2021 (June 4–8);

8 poster presentations

Past event
AACR 2021
AACR 2021

Find out about our virtual activities at the AACR annual meeting 2021 (April 10-15);

11 posters and 1 oral presentation

Past event
ELCC 2021
ELCC 2021

Find out about our activities at the ELCC virtual congress 2021 (March 25–27);

2 poster presentations

Past event
IASLC WCLC 2020
IASLC WCLC 2020

Explore data presented at the IASLC WCLC 2020 virtual meeting (January 28–31);

1 poster presentation

RESOURCES

Physicians´ insights

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

 

**Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: September 2021